The Biden administration has announced the first 10 medications that will be subject to price negotiations with Medicare under the Inflation Reduction Act.
These are the three that were most commonly used by Medicare Part D patients between June 1, 2022, and May 31, according to an Aug. 29 report from CNBC:
Eliquis, a blood thinner made by Bristol-Myers Squibb, was the most commonly used, with 3.7 million Medicare enrollees on the medication.
Jardiance, a low blood sugar medication for Type 2 diabetes made by Boehringer Ingelheim, was used by 1.6 million people.
Xarelto, a blood thinner made by Johnson & Johnson, was used by 1.3 million beneficiaries.